ClinicalTrials.gg
CompletedNCT07037966Updated Oct 1, 2026

Advancing Portable Brain Imaging: The NextMRI Project's Role in Revolutionizing Diagnostic MRI

An interventional study of MRI and MRI in Multiple Sclerosis, sponsored by Instituto de Investigacion Sanitaria La Fe. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Instituto de Investigacion Sanitaria La Fe · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 1, 2026Now CompletedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.

Enrollment
125th of 202
75 · median 137
Started
2025
with 24 others
No phase
68 of 230
22 open now
Registered
202nd of 230
by date

Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 125th largest by enrollment of the 202 interventional ones that give a count, is one of 25 that started in 2025, is one of 68 with no phase, and was the 202nd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Multiple Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

Mobile imaging diagnostic devices are extremely valuable for clinical diagnosis both inside and outside healthcare facilities. However, Magnetic Resonance Imaging (MRI)-the gold standard for diagnosing many neurological and musculoskeletal conditions-is not easily portable. Moreover, due to its high cost (in the million-euro range) and limited availability, the average wait time in Europe for an MRI scan is from several weeks to months.

The NextMRI project aims to take the technical, industrial, and commercial steps required to deploy portable low-field MRI systems in remote and developing regions, rural areas, sporting events, military or medical camps, and home healthcare settings, improving diagnostic capabilities. The specific goals of the NextMRI project are:

  1. Expand current low-field MRI technology to brain imaging.
  2. Enhance diagnostic accuracy using machine learning.
  3. Improve portability and usability for end users.
  4. Reduce production costs for broader affordability.
  5. Collect clinical evidence through trials to validate medical performance.
  6. Develop a sustainable business model for market commercialization.
Read the detailed description

Based on this context, the NextMRI project will carry out a clinical evaluation study involving a multidisciplinary team of radiologists, rheumatologists, physiotherapists, data managers, and physicists. The study will focus on patients with suspected multiple sclerosis (MS). Its main goals are to:

  1. Assess the diagnostic value of the low-field MRI prototype.
  2. Evaluate usability for end users.
  3. Train AI algorithms using deep learning to differentiate between healthy and damaged tissues, thereby aiding radiologists, reducing diagnostic time, and lightening their workload.

Radiologists will first generate structured reports based on standard high-resolution MRI scans. They will then evaluate the low-field MRI images from the NextMRI prototype. The initial high-field MRI reports will serve as the reference standard for assessing performance and training the AI system.

Each patient will undergo two MRI scans on the same day (after providing informed consent): one at the standard 3T MR scan and other at the low-field MRI scan (NextMRI). To prevent bias, both scans will be interpreted by a professional radiologist with an 8-week interval between readings.

A total of 50 patients aged between 18 and 65 years with suspected multiple sclerosis will be included. Patients with any contraindications for high-field MRI will be excluded from the study.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • multiple sclerosis
  • MRI
  • Brain Imaging
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with suspected multiple sclerosis or or undergoing clinical review/follow-up for MS

Exclusion criteria

Exclusion Criteria:

  • Any contradictions for high-field MRI
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Patients with Suspected Multiple Sclerosis

    A total of 50 patients aged between 18 and 65 years with suspected multiple sclerosis will be scanned using both the 3T MRI and the NextMRI prototype.

    Device: MRI

Interventions

  • DeviceMRI

    Standard 3T MRI Scan

  • DeviceMRI

    Low-field MRI scan using the NextMRI prototype

06

What researchers measure

Primary outcomes

  1. Radiological reports to Evaluate NextMRI prototype performance

    A clinical evaluation study will be performed involving a multidisciplinary team of radiologists, traumatologists, rheumatologists, physiotherapists, data managers and physicists. The validation strategy will be structured in 3 steps: 1. Radiologists will report the high-resolution MR images in a structured report as part of their clinical duties. 2. Radiologists will evaluate the MR images acquired with the PR Gen III scanner after 8 weeks, in order be blind to the first reading and avoid learning interobserver bias 3. Finally, the gold standard information obtained by the initial radiological report will serve to evaluate the prototype performance and train the Deep Learning tools. The report documents technical details, contrast use, and lesion analysis in brain, spine, and medulla. It quantifies key MS-related lesions, categorizes locations, and notes other abnormalities. A diagnostic impression summarizes findings to support MS diagnosis.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Patient Comfort and Satisfaction Questionnaire to Evaluate the New NextMRI Prototype Compared to the Standard MRI Scanner

    Patients provide insights into their experiences with both scanners, focusing on aspects such as ease of entry and exit, comfort during positioning, perception of claustrophobia, noise levels, and overall satisfaction. Additionally, they compare the two scanners directly, offering valuable perspectives on which device they prefer and why. Their comments highlight subjective comfort and practical challenges, which are critical for improving patient-centered design. The Questionnaire will use a Likert scale (e.g., from 1 = very uncomfortable to 5 = very comfortable) combined with open-ended questions for additional comments.

    Time frame: 1 year

  2. User Comfort and Satisfaction Questionnaire Evaluate the New NextMRI Prototype Compared to the Standard MRI Scanner

    Healthcare professionals, including radiologists and MRI technicians, evaluate the scanners from an operational standpoint. Their feedback covers ease of use, image quality, workflow efficiency, technical issues, and overall satisfaction with the device's performance. They also compare the NextMRI prototype to the standard scanner, assessing its potential impact on clinical practice, particularly for patients with conditions like Multiple Sclerosis. Professionals are asked to identify any anticipated challenges in implementation and to suggest additional training or resources needed for optimal use. The Questionnaire will use a Likert scale (e.g., from 1 = very uncomfortable to 5 = very comfortable) combined with open-ended questions for additional comments.

    Time frame: 1 year

07

Study locations

1 site
  • Hospital Universitario y Politécnico la Fe
    Valencia, Valencia 46026, Spain
08

References and documents

Publications

  • Guallart-Naval T, Algarin JM, Pellicer-Guridi R, Galve F, Vives-Gilabert Y, Bosch R, Pallas E, Gonzalez JM, Rigla JP, Martinez P, Lloris FJ, Borreguero J, Marcos-Perucho A, Negnevitsky V, Marti-Bonmati L, Rios A, Benlloch JM, Alonso J. Portable magnetic resonance imaging of patients indoors, outdoors and at home. Sci Rep. 2022 Jul 30;12(1):13147. doi: 10.1038/s41598-022-17472-w. PubMed 35907975 ↗
  • O'Reilly T, Teeuwisse WM, de Gans D, Koolstra K, Webb AG. In vivo 3D brain and extremity MRI at 50 mT using a permanent magnet Halbach array. Magn Reson Med. 2021 Jan;85(1):495-505. doi: 10.1002/mrm.28396. Epub 2020 Jul 5. PubMed 32627235 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Jun 2026, 7 months.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 7 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jun 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
Jun 26, 2025
StartActual
Nov 7, 2025
Primary completionActual
Jun 12, 2026was Sep 2026
CompletionActual
Sep 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 1, 2026
Sites
1 site added, 1 site removed
Show site
  • Hospital Universitario y Politécnico la Fe · Valencia, Spain
Show 1 removed
  • Hospital Universitario y Politécnico la Fe · Valencia, Spain
Oct 1, 2026
Primary completion
Sep 2026→Jun 12, 2026 (actual)
Oct 1, 2026
Enrollment
50 (estimated)→75 (actual)
Oct 1, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Patients with suspected multiple sclerosisNow Patients with suspected multiple sclerosis or or undergoing clinical review/follow-up for MS
Oct 1, 2026
Documents
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Recruiting→Completed
    Documents Study protocol ↗ posted
    1 site added, 1 site removed
    Show site
    • Hospital Universitario y Politécnico la Fe · Valencia, Spain
    Show 1 removed
    • Hospital Universitario y Politécnico la Fe · Valencia, Spain
    Primary completion Sep 2026→Jun 12, 2026 (now actual)
    Enrollment 50 (estimated)→75 (actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Patients with suspected multiple sclerosisNow Patients with suspected multiple sclerosis or or undergoing clinical review/follow-up for MS
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07037966
Lead sponsor
Instituto de Investigacion Sanitaria La Fe
Collaborators
National Research Council, Spain
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Nov 7, 2025
Primary completion
Jun 12, 2026
Completion
Sep 1, 2026
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion